BRIEF—Alnylam publishes pivotal patisiran study in New England Journal of Medicine

Alnylam Pharmaceuticals, a Massachussets biotech, has announced that its pivotal Phase III data from the APOLLO trial has been published in the New England Journal of Medicine (NEJM).

It is the first time an RNAi clinical trial has been published in a peer-reviewed journal of the NEJM's stature, and is focused on patisiran's ability to treat hereditary ATTR amyloidosis, a debilitating and generally fatal disease.

Some of the points of interest from the study include the transition of some patients from disease progression to remission; the restoration of some patients' ability to walk unassisted; and a variety of general improvements made to patient quality of life.

As of July 11, Alnylam shares have risen by nearly 7% since the data was published.